U.S. patent application number 13/113136 was filed with the patent office on 2011-11-24 for bimatoprost crystalline form i.
Invention is credited to Arie GUTMAN, Gennady Nisnevich, Boris Pertsikov, Igor Rukhman, Boris Tishin, Alexander Vilensky, Lev Yudovich.
Application Number | 20110288179 13/113136 |
Document ID | / |
Family ID | 40789390 |
Filed Date | 2011-11-24 |
United States Patent
Application |
20110288179 |
Kind Code |
A1 |
GUTMAN; Arie ; et
al. |
November 24, 2011 |
BIMATOPROST CRYSTALLINE FORM I
Abstract
The invention provides a novel polymorphic form I of crystalline
bimatoprost, method for preparation thereof and new crystalline
intermediates in the preparation. This form I of crystalline
bimatoprost is used in purification of crude bimatoprost and in
storage of bimatoprost as active pharmaceutical intermediate. Use
of the physical form of bimatoprost in the manufacture of a
medicament is also disclosed.
Inventors: |
GUTMAN; Arie; (Haifa,
IL) ; Rukhman; Igor; (Haifa, IL) ; Tishin;
Boris; (Haifa, IL) ; Yudovich; Lev; (Haifa,
IL) ; Vilensky; Alexander; (Haifa, IL) ;
Pertsikov; Boris; (Nesher, IL) ; Nisnevich;
Gennady; (Haifa, IL) |
Family ID: |
40789390 |
Appl. No.: |
13/113136 |
Filed: |
May 23, 2011 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11896002 |
Aug 29, 2007 |
7947740 |
|
|
13113136 |
|
|
|
|
Current U.S.
Class: |
514/622 ;
564/171 |
Current CPC
Class: |
A61K 9/0048 20130101;
C07C 2601/08 20170501; C07F 7/1804 20130101; C07C 405/00 20130101;
A61P 27/02 20180101 |
Class at
Publication: |
514/622 ;
564/171 |
International
Class: |
A61K 31/166 20060101
A61K031/166; C07C 233/11 20060101 C07C233/11 |
Foreign Application Data
Date |
Code |
Application Number |
Aug 29, 2006 |
IL |
177762 |
Claims
1. A pure bimatoprost, wherein said bimatoprost contains (by HPLC)
not more than (NMT) 2% of sum of all related impurities and 1% of
5-trans isomer.
2. The pure bimatoprost according to claim 1, wherein said
bimatoprost contains (by HPLC) not more than (NMT) 1.5% of sum of
all related impurities and 0.7% of 5-trans isomer.
3. The pure bimatoprost according to claim 1, wherein said
bimatoprost contains (by HPLC) not more than (NMT) 1% of sum of all
related impurities and 0.5% of 5-trans isomer.
4. The pure bimatoprost according to claim 1, wherein said
bimatoprost is free of 5-trans and 15(R)-isomers of
bimatoprost.
5. The pure bimatoprost according to claim 1, wherein said
bimatoprost contains by LC not more than (NMT) 0.2% each of 5-trans
isomer and 15(R) isomer.
6. The pure bimatoprost according to claim 1, wherein said
bimatoprost contains by LC not more than (NMT) 0.1% each of 5-trans
isomer and 15(R) isomer.
7. The pure bimatoprost according to claim 1, wherein said
bimatoprost contains by LC not more than (NMT) 0.05% each of
5-trans isomer and 15(R) isomer.
8. A method for preparing a pharmaceutical or cosmetic composition
by combining effective amount of said bimatoprost according to
claim 1 with a pharmaceutical or cosmetic acceptable vehicle.
9. Use of crystalline form I of bimatoprost for the preparation of
pure bimatoprost.
Description
CROSS REFERENCE OF APPLICATION
[0001] This application is a Continuation of U.S. patent
application Ser. No. 11/896,002, filed Aug. 29, 2007 which claims
priority of Israeli Application Number 177762, filed Aug. 29, 2006,
which is hereby incorporated by reference in its entirety.
FIELD OF THE INVENTION
[0002] The invention relates to novel polymorphic form I of
crystalline bimatoprost, method for preparation thereof and new
crystalline intermediates in the preparation. This form I of
crystalline bimatoprost is used in purification of crude
bimatoprost, and in storage of bimatoprost as active pharmaceutical
intermediate. Use of the physical form of bimatoprost in the
manufacture of a medicament is also disclosed.
BACKGROUND OF THE INVENTION
[0003] Elevated intraocular pressure (TOP) is the major risk factor
associated with the etiology of glaucoma, a progressive optic
neuropathy that can ultimately cause blindness. Prostamide analogs
represent potent therapeutic agents in clinical management of
glaucoma and other conditions associated with elevated intraocular
pressure. The synthetic prostamide analog used to reduce IOP
includes
(9S,11R,15S)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-5Z,13E-prostadi-
enoic acid ethylamide
##STR00001##
known under international nonproprietary name bimatoprost,
currently marketed by Allergan as Lumigan.TM.--0.03% bimatoprost
ophthalmic solution for the treatment of open-angle glaucoma and
ocular hypertension (Drugs Aging, 2002, 19, 231).
[0004] US2005/209337 discloses crystalline physical form of
bimatoprost, which we designate as form A. The form is
characterized by powder x-ray diffractometry, IR DRIFTS (KBr)
spectroscopy, DSC and TGA. The present invention includes new
polymorphic form of bimatoprost which is the most thermodynamically
stable polymorph of bimatoprost and method for preparation
thereof.
SUMMARY OF THE INVENTION
[0005] The present invention provides crystalline form I of
bimatoprost and method for preparation thereof. The new crystalline
form of bimatoprost is the most stable solid form of bimatoprost.
Moreover, the new form of bimatoprost may be prepared so as to be
substantially free of other physical forms.
[0006] The present invention also provides a method for purifying
crude bimatoprost from related impurities, which comprises the
steps of:
a) dissolving crude bimatoprost in an organic solvent or a mixture
of organic solvent and anti-solvent at or near the boiling point;
b) allowing the hot solution to cool; c) separating the precipitate
from the supernatant solution; d) drying the resulting solid in
vacuo at low temperature and then at 30 to 40.degree. C. to give
purified bimatoprost in crystalline form I.
[0007] The present invention also provides the use of bimatoprost
crystalline form I in the manufacture of a medicament. The
medicament is prepared by combining a therapeutically effective
amount of bimatoprost crystalline form I, as an active ingredient,
with conventional pharmaceutically-acceptable excipients, e.g. an
ophthalmically-acceptable vehicle, and by preparation of unit
dosage forms suitable for pharmaceutical use, e.g. topical ocular
use.
[0008] The present invention also provides new crystalline
intermediate in the synthesis of bimatoprost-crystalline
(3aR,4R,5R,6aS)-4-[3R-(t-butyldimethylsiloxy)-5-phenyl-1E-pentenyl]-5-(4--
phenylbenzoyloxy)-hexahydro-2H-cyclopenta[b]furan-2-one 5a.
##STR00002##
[0009] The crystalline intermediate is useful for complete
isolation of desired crystalline
(3aR,4R,5R,6aS)-4-[3S-(t-butyldimethylsiloxy)-5-phenyl-1E-pentenyl]-5-(4--
phenylbenzoyloxy)-hexahydro-2H-cyclopenta[b]furan-2-one 5 as MTBE
solvate
##STR00003##
from reaction mixture and for recovery of by-product.
BRIEF DESCRIPTION OF THE DRAWINGS
[0010] FIG. 1 shows a characteristic x-ray powder diffraction
pattern of bimatoprost crystalline form I, according to embodiments
of the present invention. Vertical axis: intensity (counts per
second); Horizontal axis: 20 (degrees).
[0011] FIG. 2 shows the differential scanning calorimetry (DSC)
curve of bimatoprost crystalline form I, according to embodiments
of the invention.
[0012] FIG. 3 shows the infrared spectrum (diffuse reflectance,
DRIFTS) of bimatoprost crystalline form I in potassium bromide,
according to embodiments of the invention.
[0013] FIG. 4 shows the infrared spectrum of bimatoprost
crystalline form I in potassium bromide, according to embodiments
of the invention.
[0014] FIG. 5 shows the infrared spectrum of bimatoprost
crystalline form I in Nujol, according to embodiments of the
invention.
[0015] FIG. 6 shows the .sup.1H nuclear magnetic resonance (NMR)
spectrum of compound 5 MTBE solvate in CDCl.sub.3, according to
embodiments of the invention.
[0016] FIG. 7 shows a characteristic x-ray powder diffraction
pattern of compound 5 MTBE solvate, according to embodiments of the
present invention. Vertical axis: intensity (counts per second);
Horizontal axis: 2.theta. (degrees).
[0017] FIG. 8 shows the infrared spectrum (diffuse reflectance,
DRIFTS) of compound 5 MTBE solvate in potassium bromide, according
to embodiments of the invention.
[0018] FIG. 9 shows the differential scanning calorimetry (DSC)
curve of compound 5 MTBE solvate, according to embodiments of the
invention.
[0019] FIG. 10 shows the thermograviometric (TGA) curve of compound
5 MTBE solvate, according to embodiments of the invention.
[0020] FIG. 11 shows the .sup.1H nuclear magnetic resonance (NMR)
spectrum of compound 5a in CDCl.sub.3, according to embodiments of
the invention.
[0021] FIG. 12 shows a characteristic x-ray powder diffraction
pattern of compound 5a, according to embodiments of the present
invention. Vertical axis: intensity (counts per second); Horizontal
axis: 2.theta. (degrees).
[0022] FIG. 13 shows the infrared spectrum (KBr) of compound 5a in
potassium bromide, according to embodiments of the invention.
[0023] FIG. 14 shows the differential scanning calorimetry (DSC)
curve of compound 5a, according to embodiments of the
invention.
DETAILED DESCRIPTION OF THE INVENTION
[0024] US2005/209337 discloses crystalline physical form of
bimatoprost, which we designate as form A. The present invention
discloses, according to its first aspect, a new crystalline form of
bimatoprost, which we designate as form I. Moreover, the
bimatoprost crystalline form I may be prepared so as to be
substantially free of other physical forms.
[0025] The present invention provides a process for producing
crystalline form I substantially free from other physical forms of
bimatoprost by crystallization of bimatoprost in any physical form
from an organic solvent or from a mixture of organic solvent and
anti-solvent. Preferably, the crystallization comprises the steps
of:
a) dissolving crude bimatoprost in an organic solvent or a mixture
of organic solvent and anti-solvent at or near the boiling point;
b) allowing the hot solution to cool; c) separating the precipitate
from the supernatant solution; d) drying the resulting solid in
vacuo at low temperature and then at 30 to 40.degree. C. to yield
bimatoprost crystalline form I substantially free from other
physical forms.
[0026] The said organic solvent is selected from the group
consisting of alcohols, esters, ketones, chloroorganic solvents, or
mixture thereof. Preferably, said alcohols are selected from the
group consisting of methanol, ethanol, isopropanol, butanol,
isobutanol, t-butanol or mixture thereof. Preferably, said esters
are selected from the group consisting of ethyl acetate, isopropyl
acetate, butyl acetate or mixture thereof. Preferably, said ketones
are selected from the group consisting of acetone, methyl ethyl
ketone, isopropylacetone or mixture thereof. Preferably, said
chloroorganic solvents are selected from the group consisting of
dichloromethane, chloroform, chlorobenzene or mixture thereof.
[0027] The said anti-solvent is selected from the group consisting
of hydrocarbons, ethers or mixture thereof. Preferably, the
anti-solvent is saturated hydrocarbon. Preferably, said saturated
hydrocarbon is selected from the group consisting of pentane,
heptane, hexane, cyclohexane or mixture thereof. Preferably, said
ethers are selected from the group consisting of diethyl ether,
diisopropyl ether, MTBE or mixture thereof.
[0028] A pure crystalline organic compound has, in general, a
definite melting point range. The melting point is defined as the
point at which the sample is entirely in the liquid phase.
Bimatoprost crystalline form I has a characteristic melting point
range determined by the capillary method from 62 to 64.degree.
C.
[0029] Differential scanning calorimetry (DSC), x-ray powder
diffraction (XRPD) and infrared (IR) spectroscopy were used to
characterize the new form.
[0030] The DSC curve of form I (FIG. 2) exhibits a melting
endotherm at approximately 60-66.degree. C.
[0031] Bimatoprost crystalline form I also exhibits distinctive
x-ray powder diffraction pattern, as depicted in FIG. 1. The
pattern has characteristic peaks expressed in degrees 20 at
approximately 5.4.+-.0.2, 10.9.+-.0.2, 11.3.+-.0.2, 13.7.+-.0.2,
16.6.+-.0.2, 17.5.+-.0.2, 19.9.+-.0.2, 20.7.+-.0.2 and
22.7.+-.0.2.
[0032] The crystalline form I was characterized by an infrared
diffuse reflectance spectrum in potassium bromide as depicted in
FIG. 3. The crystalline form I was further characterized by an
infrared absorption spectrum carried out in potassium bromide and
in Nujol as depicted in FIGS. 4 and 5.
[0033] Bimatoprost crystalline form I is the most stable
crystalline modification of bimatoprost in a temperature range
between -70 and +30.degree. C. Stability data supports the retest
period of not less than 6 months if bimatoprost crystalline form I
is stored in an appropriate container at 2 to 8.degree. C. and at
25.degree. C.
[0034] The importance of bimatoprost crystalline form I rests
primarily (but not exclusively) in its thermodynamic stability.
Besides its greater stability, form I shows advantages with respect
to form A because of the possibility of its preparation by
crystallization employing different solvents in a wide temperature
range. For example, the crystalline form I may be easily prepared
by recrystallizing, triturating, or reslurring of crystalline form
A.
[0035] Crude non-crystalline bimatoprost may be prepared by
amidation of bimatoprost acid 3
##STR00004##
with ethylamine optionally in the presence of carbodiimides.
Preferably, the carbodiimides are selected from the group of
N,N-dicyclohexylcarbodiimide (DCC) and
N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide (EDC). Preferably,
crude bimatoprost is prepared by reaction of bimatoprost acid
methyl ester with ethylamine as described in US2004/171873,
US2005/209337, US2005/154220 and U.S. Pat. No. 5,352,708.
[0036] Methyl ester of bimatoprost acid 2
##STR00005##
may be prepared by reacting of bimatoprost acid 3 with methylation
agent MeY wherein Y is a leaving group, in the presence of
base.
[0037] Preferably, the methylation agent is methyl iodide, bromide,
methanesulfonate, p-toluenesulfonate, 2,4-dinitrophenylsulfonate or
triflate.
[0038] Optionally, the base is 1,8-diazabicyclo[5.4.0]undec-7-ene
(DBU). Preferably, the base is K.sub.2CO.sub.3. Most preferably,
the base is cesium carbonate, hydrogencarbonate, hydroxide or
fluoride or mixture thereof. If cesium alkali is used as base in
the methylation reaction cesium salt of bimatoprost acid
##STR00006##
is obtained as intermediate in the reaction.
[0039] Preferably, the methylation reaction of bimatoprost acid 3
is provided in the presence of solvent. Preferably, the solvent is
aprotic organic solvent. More preferably, the solvent is polar
organic solvent. For example, the polar organic solvent is
N,N-dimethylformamide (DMF), N,N-dimethylacetamide,
1-methyl-2-pyrrolidinone (NMP), dimethyl sulfoxide (DMSO),
sulfolane or HMPA. Preferably the solvent is DMF.
[0040] The bimatoprost acid methyl ester 2 prepared by the reaction
may be used in following amination reaction without purification;
however ester 2 may be purified by flash chromatography. Preferably
the purification is provided by preparative LC on silica gel or
Phenomenex.TM. Luna CN silica gel.
[0041] According to embodiment of the invention, the bimatoprost
acid 2 is prepared by Wittig reacting of lactol
##STR00007##
with a metal salt of 5-(triphenylphosphoranylidene)pentanoic acid
following by desilylation of intermediate protected bimatoprost
acid.
##STR00008##
[0042] Preferably, the Wittig reaction is provided in the presence
of aprotic organic solvent. More preferably, the solvent is
ether-type solvent. Most preferably the solvent is THF. Analytical
HPLC showed that crude bimatoprost acid 3 prepared by the Wittig
reaction contains up to 5% of 5-trans isomer 3b.
##STR00009##
[0043] The lactol 4 may be prepared by reducing compound of
formula
##STR00010##
wherein with i-Bu.sub.2AlH at temperature range from -80 to
-50.degree. C. Preferably, the reaction temperature range is -50 to
+20.degree. C., more preferably -30 to 0.degree. C. To increase the
yield of lactol 4 it is desirable to add i-Bu.sub.2AlH to lactone 5
at -50 to +20.degree. C. (preferably at -30 to 0.degree. C.) to
attain about 95-99% conversion of lactone group. Preferably, the
reaction is provided in the presence of aprotic organic solvent.
More preferably, the solvent is toluene, CH.sub.2Cl.sub.2, THF,
ether or mixture thereof.
[0044] The process of the present invention for the synthesis of
bimatoprost may be summarized by the Scheme 1. Analytical HPLC
showed that crude bimatoprost 1 prepared according to Scheme 1
contains up to 5% of 5-trans isomer 1b (from the Wittig
reaction).
##STR00011##
[0045] In one embodiment of the invention, the lactone 5 is
prepared by process comprising:
reduction of the carbonyl group of ketone 7
##STR00012##
to yield a mixture of compounds of formulae 6 and 6a
##STR00013##
which are subsequently converted into a mixture of compounds 5
and
##STR00014##
followed by isolation of the compounds 5 and 5a from the
mixture.
[0046] The process for the synthesis of compound 5 from enone 7 may
be summarized by the following Scheme 2:
##STR00015##
[0047] Basis of the synthesis is easy separation of lactone 5 as
crystalline MTBE solvate from mixture of 5 and 5a isomers. The
potential of the separation method may be illustrated by isolation
of highly pure lactone 5 as MTBE solvate with 40% recovery and
lactone 5a as solvent free crystalline compound with 33% recovery
by serial of simple crystallizations of 1:1 mixture of 5 and 5a
isomers from MTBE and hydrocarbon solvent.
[0048] The reduction of the compound 6 may be carried out with any
reagent capable to reduce ketone function to alcohol. An example of
the reagent is NaBH.sub.4 or (i-PrO).sub.3Al. Preferably the
reduction of the compound 6 is carried out with
(-)-B-chlorodiisopinocampheylborane or with borane in the presence
of 2-alkyl-CBS-oxazaborolydines. More preferably the reduction is
carried out with (-)-B-chlorodiisopinocamphenylborane in organic
solvent. Preferably the organic solvent is THF, ether,
1,2-dimethoxyethane, toluene, hexane, CH.sub.2Cl.sub.2 or mixtures
of these solvents.
[0049] In another embodiment of the invention, the invention
provides crystalline MTBE solvate of
(3aR,4R,5R,6aS)-4-[3S-(t-butyldimethylsiloxy)-5-phenyl-1E-pentenyl]-5-(4--
phenylbenzoyloxy)-hexahydro-2H-cyclopenta[b]furan-2-one 5
##STR00016##
[0050] Crystalline MTBE solvate of lactone 5 has a characteristic
melting point range determined by the capillary method from 60 to
64.degree. C.
[0051] Differential scanning calorimetry (DSC), x-ray powder
diffraction (XRPD) and infrared (IR) spectroscopy were used to
characterize the new form.
[0052] Crystalline lactone 5 MTBE solvate (FIG. 9) exhibits a
melting endotherm at approximately 60-66.degree. C.
[0053] Crystalline lactone 5 MTBE solvate also exhibits distinctive
x-ray powder diffraction pattern, as depicted in FIG. 7. The
pattern has characteristic peaks expressed in degrees 20 at
approximately 6.5.+-.0.2, 7.1.+-.0.2, 12.2.+-.0.2, 12.5.+-.0.2,
13.1.+-.0.2, 13.6.+-.0.2, 14.6.+-.0.2, 15.0.+-.0.2, 15.8.+-.0.2,
16.2.+-.0.2, 16.3.+-.0.2, 17.0.+-.0.2, 17.3.+-.0.2, 18.0.+-.0.2,
18.2.+-.0.2, 18.8.+-.0.2, 19.5.+-.0.2, 19.7.+-.0.2, 20.5.+-.0.2,
20.8.+-.0.2, 21.0.+-.0.2, 21.8.+-.0.2, 22.2.+-.0.2, 23.0.+-.0.2,
23.3.+-.0.2, 24.2.+-.0.2, 25.5.+-.0.2, 26.5.+-.0.2 and
26.7.+-.0.2.
[0054] The crystalline lactone 5 MTBE solvate was characterized by
an infrared diffuse reflectance spectrum in potassium bromide as
depicted in FIG. 8. The crystalline lactone 5
[0055] MTBE solvate was further characterized by .sup.1H NMR
spectrum carried out in CDCl.sub.3 as depicted in FIG. 11.
[0056] In another embodiment of the invention, the invention
further provides crystalline
(3aR,4R,5R,6aS)-4-[3R-(t-butyldimethylsiloxy)-5-phenyl-1E-pentenyl]-5-(4--
phenylbenzoyloxy)-hexahydro-2H-cyclopenta[b]furan-2-one 5a.
##STR00017##
[0057] Crystalline lactone 5a has a characteristic melting point
range determined by the capillary method from 93 to 94.degree.
C.
[0058] Crystalline lactone 5a (FIG. 14) exhibits a melting
endotherm at approximately 83-97.degree. C.
[0059] Crystalline lactone 5a also exhibits distinctive x-ray
powder diffraction pattern, as depicted in FIG. 12. The pattern has
characteristic peaks expressed in degrees 20 at approximately
5.7.+-.0.2, 6.3.+-.0.2, 14.0.+-.0.2, 14.5.+-.0.2, 14.8.+-.0.2,
15.5.+-.0.2, 16.3.+-.0.2, 17.0.+-.0.2, 17.5.+-.0.2, 17.8.+-.0.2,
18.1.+-.0.2, 18.6.+-.0.2, 18.9.+-.0.2, 19.3.+-.0.2, 21.5.+-.0.2,
22.0.+-.0.2, 22.4.+-.0.2 and 23.8.+-.0.2.
[0060] Lactone 5a was characterized by .sup.1H NMR (CDCl.sub.3),
powder x-ray diffractometry, DSC, and IR (KBr) spectroscopy as set
forth above and illustrated in FIGS. 11-14.
[0061] Crystallinity of compounds 5 (as MTBE solvate) and 5a give
very rare option to isolate the compounds in highly pure form with
high yield from 5/5a 1:1 mixture by simple crystallization
procedure.
[0062] In another embodiment of the invention, it is proposed
process for utilization of undesired compound 5a to compound 7
which process comprises the steps of converting compound 5a into
compound 6a and oxidizing the hydroxyl group of the compound
6a.
[0063] According to embodiment of the invention, the compound of
the formula 7 may be prepared by Horner-Emmons-Wadsworth reaction
of Corey aldehyde of formula 8
##STR00018##
with a .beta.-ketophosphonate BnCH.sub.2COCH.sub.2PO(OMe).sub.2 in
the presence of base. Preferably, the base is BuLi, NaH or
Et.sub.3N/LiCl. More preferably, the base is alkali. For example
the alkali is LiOH, NaOH, KOH, CsOH, Na.sub.2CO.sub.3,
K.sub.2CO.sub.3 or Cs.sub.2CO.sub.3. Most preferably, the base is
an aqueous alkali. Preferably, the Horner-Emmons-Wadsworth reaction
is provided in the presence of organic solvents. For example, the
solvent is CH.sub.2Cl.sub.2, CHCl.sub.3, toluene, THF, MTBE, ether
or mixture thereof.
[0064] According to embodiment of the invention, Corey aldehyde 8
may be prepared by oxidation of (-)-Corey lactone
5-(4-phenylbenzoate) of formula 9
##STR00019##
[0065] The oxidation of (-)-Corey lactone 5-(4-phenylbenzoate) 9
may be carried out with any oxidizing system capable to oxidize
primary alcohol to aldehyde. An example of the oxidizing system is
CrO.sub.3/C.sub.5H.sub.5N, Cl.sub.2/PhSMe, DMSO/DCC/ft, or
Dess-Martin reagent. Preferably, the oxidizing system is aq
NaClO/TEMPO, more preferably aq NaClO/TEMPO/NaBr, most preferably
NaClO/TEMPO/NaBr/1-PrOH.
[0066] The process for the synthesis of enone 7 from (-)-Corey
lactone 5-(4-phenylbenzoate) 9 may be summarized by the following
Scheme 3:
##STR00020##
[0067] The major related impurities in bimatoprost that can be
formed during synthesis or storage of bimatoprost, included the
following:
[0068] methyl ester of bimatoprost acid 2:
##STR00021##
[0069] bimatoprost acid 3:
##STR00022##
[0070] 5-trans bimatoprost 1b:
##STR00023##
[0071] 15(R) bimatoprost 1a:
##STR00024##
[0072] 15-keto bimatoprost 1c:
##STR00025##
[0073] As mentioned above, impurities 5-trans bimatoprost 1b,
15R-bimatoprost 1a, 15-keto bimatoprost 1c could be formed during
synthesis or storage of bimatoprost. These compounds were
synthesized as analytical markers for HPLC analysis and
characterized. We prepared 15R-bimatoprost 1a from lactone 5a
according to Scheme 4.
##STR00026##
[0074] 5-trans Bimatoprost 1b was prepared from methyl ester 2
according to Scheme 5.
##STR00027##
[0075] The key step of the synthesis is isomerisation of methyl
ester 10 to its 5-trans isomer 11 by irradiation in the presence of
Ph.sub.2S.
[0076] 15-keto Bimatoprost 1c was prepared by selective oxidation
of 15-hydroxy group of bimatoprost.
[0077] It has been found that the 5-trans and 15R-isomers of
bimatoprost are particularly difficult to remove because they have
similar physical and chemical properties to bimatoprost. We found
that it is possible to separate of bimatoprost from the impurities
using an HPLC purification system. However the HPLC purification is
expensive and is not practical for large scale separations.
[0078] These problems have been solved by the use of crystalline
form I in purification of bimatoprost. The present invention
provides a method for purifying crude bimatoprost from related
impurities, which comprises the steps of:
a) dissolving crude bimatoprost in an organic solvent or a mixture
of organic solvent and anti-solvent under reflux conditions; b)
allowing the hot solution to cool; c) separating the precipitate
from the supernatant solution; d) drying the resulting solid in
vacuo at low temperature and then at 30 to 40.degree. C. to give
bimatoprost crystalline form I with desired LC purity.
[0079] By using the process of the present invention, it has been
found possible to produce bimatoprost that is substantially free of
15R- and 5-trans isomers of bimatoprost. Using the process of the
present invention, bimatoprost containing less than 0.2% each of
15R- and 5-trans isomers can be produced. In particular,
bimatoprost containing less than 0.1% each of 15R- and 5-trans
isomers can be produced. Preferably, bimatoprost containing less
than 0.05% each of 15R- and 5-trans isomers can be produced.
[0080] The above processes thus enable bimatoprost having an
extremely high degree of purity can be obtained, e.g. greater than
98% pure, greater than 99% pure, greater than 99.5% pure. Indeed,
it has been found possible to achieve bimatoprost purities of
greater than 99.8%.
[0081] The present invention also provides the use of bimatoprost
crystalline form I in the manufacture of a medicament. The
medicament is prepared in two steps, preparation of a composition
containing bimatoprost and manufacture of unit dosage forms
suitable for pharmaceutical use, e.g. topical ocular use.
Preferably, the composition is prepared by combining a
therapeutically effective amount of bimatoprost crystalline form I,
as an active ingredient, with conventional
pharmaceutically-acceptable excipients, e.g. an
ophthalmically-acceptable vehicle. The therapeutically efficient
amount typically is between about 0.0001 and about 5% (w/v),
preferably about 0.001 to about 1.0% (w/v) in liquid
formulations.
[0082] In addition to the above-described principal active
ingredients, the compositions of the present invention may further
comprise various formulatory ingredients, such as ophthalmically
acceptable diluents, buffers, hydrochloric acid, sodium hydroxide,
antimicrobial preservatives, stabilizers, tonicity adjustors,
viscosity-enhancing agents, chelating agents, antioxidants,
surfactants and/or solubilizers and combinations thereof.
[0083] Preferably, the diluent is purified water.
[0084] Preservatives are used in multi-use ophthalmic formulations
to prevent microbial contamination of the composition after the
packaging has been opened. A number of preservatives have been used
including quaternary ammonium salts, mercury compounds, alcohols
and stabilized chlorine dioxide. Preferred preservatives that may
be used in the pharmaceutical compositions of the present invention
include benzalkonium chloride, chlorobutanol, thimerosal,
phenylmercuric acetate, methyl paraben, propyl paraben, phenylethyl
alcohol, edetate disodium, sorbic acid, phenylmercuric nitrate,
Polyquad.TM..
[0085] Viscosity-enhancing agents may be added as needed or
convenient. They include, but are not limited to, sodium
carboxymethylcellulose, hydroxypropylmethylcellulose, povidone,
polyvinyl alcohol, polyethylene glycol, or combinations
thereof.
[0086] Tonicity adjustors may be added as needed or convenient.
They include, but are not limited to, salts, particularly sodium
chloride, potassium chloride, mannitol, dextrose, propylene glycol
and glycerin, or any other suitable ophthalmically acceptable
tonicity adjustor.
[0087] Various buffers and means for adjusting pH may be used so
long as the resulting preparation is ophthalmically acceptable.
Accordingly, buffers include acetate buffers, citrate buffers,
phosphate buffers and borate buffers. Hydrochloric acid or sodium
hydroxide may be used to adjust the pH of these formulations as
needed.
[0088] Preferred surfactants are, for example, polyethoxylated
castor oil, Tween 80, polyvinyl alcohol, povidone, hydroxypropyl
methyl cellulose, poloxamers, carboxymethyl cellulose and
hydroxyethyl cellulose cyclodextrin.
[0089] Other excipient components, which may be included in the
ophthalmic preparations, are chelating agents. The preferred
chelating agent is edentate disodium, although other chelating
agents may also be used in place of or in conjunction with it.
[0090] The following abbreviations are used:
(-)-DIP-Chloride.TM.
(Sigma-Aldrich)=(-)-B-chlorodiisopinocampheylborane
[0091] Bn=benzyl; br.=broad; Bu=n-butyl; i-Bu=i-butyl; d=doublet;
DBU=1,8-diazabicyclo[5.4.0]undec-7-ene;
i-Bu.sub.2AlH=diisobutylaluminium hydride;
DMAP=4-N,N-dimethylaminopyridine;
DMF=N,N-dimethylformamide;
[0092] DMSO=dimethyl sulfoxide; DRIFTS=diffuse reflectance infrared
Fourier-transform spectrum (spectroscopy); DSC=differential
scanning calorimetry; FT-IR=Fourier-transform infrared; GC=gas
chromatography; HPLC=high performance liquid chromatography;
HMPA=hexamethylphosphoramide;
INN=International Nonproprietary Name;
[0093] IOP=intraocular pressure; i-PrOH=isopropanol; IR=infrared;
LC=liquid chromatography; m=multiplet; MTBE=tert-butyl methyl
ether; NMT=not more than; NMP=1-methyl-2-pyrrolidinone; NMR=nuclear
magnetic resonance; PPB=4-phenylbenzoyl; PPTS=pyridinium
p-toluenesulfonate; rt=room temperature; s=singlet; t=triplet;
THF=tetrahydrofuran; TGA=thermogravimetric analysis;
USAN=United States Adopted Name;
[0094] XRPD=x-ray powder diffraction.
[0095] The following example is illustrative, but not limiting, of
the methods of the present invention. Other suitable modifications
and adaptations of the variety of conditions and parameters
normally encountered in chemical synthesis and which are obvious to
those skilled in the art are within the spirit and scope of the
invention.
EXAMPLES
Experimental Details
[0096] All reagents and solvents were purchased from Aldrich
Chemical Company unless specified otherwise and used without
further purification. All reactions were provided under argon or
nitrogen atmosphere.
[0097] The LC purity was determined by separating a sample by High
performance liquid chromatography (HPLC) and calculating the area
percentage thereof of each peak. The chromatographic analysis of
bimatoprost is based on a chiral reversed-phase HPLC method with an
optically active tris(3,5-dimethylphenylcarbamate) of cellulose
immobilized on silica support stationary phase and a mobile phase
buffered at pH 4.5. HPLC method was carried out using a 10 .mu.m
Chiralpak.TM. OD-R 250.times.4.6 mm column (Diacel).
Diluent--mixture A/B 25:75, sample concentration--about 0.5 mg per
1 mL, injection volume--20 .mu.L; a mobile phase--gradient A/B
25:75 for 0 min, 25:75 for 25 min, 35:65 for 35 min, 35:65 for 60
min, 25:75 for 65 min, 25:75 for 80 min wherein A is MeCN and B is
Et.sub.3N (1.0 mL) solution in water (1 L), pH adjusted with 85%
H.sub.3PO.sub.4 up to 4.5. Column temperature 35.degree. C.; a flow
rate of 0.7 mL/min; and a UV detector at 200 nm.
[0098] NMR spectra were recorded on a Bruker AM-200 (.sup.1H at 200
MHz, .sup.13C at 50 MHz) and Bruker AM-400 (.sup.1H at 400 MHz)
instruments using CDCl.sub.3 (unless otherwise stated) as a
solvent, and chemical shifts are in 6 (ppm) relative to internal
TMS.
[0099] Infrared (IR) absorption spectra were obtained by Nicolet
Impact 410 FT-IR spectrophotometer using a dispersion of solid
sample material in KBr or Nujol. Infrared DRIFTS spectra were
obtained by Nicolet Impact 410 FT-IR spectrophotometer equipped
with Pike Technologies EasiDiff Diffuse Reflectance Accessory using
a dispersion of solid sample material in KBr.
[0100] Powder x-ray diffraction patterns were obtained by methods
known in the art using PANALYTICAL (Philips) X'Pert Pro MPD x-ray
powder diffraction system (CuK.sub..alpha. radiation, PW3050/60
goniometer, PW3015/20 X'Celerator detector). The Bragg-Brentano
scheme was used for beam focusing.
[0101] Melting points were determined in open capillary tubes with
Buchi B-545 capillary melting point apparatus or Mettler-Toledo
FP-900 Thermosystem with FP-81 HT Melting Point Cell and FP-90
central processor, or Electrothermal IA 9300 digital melting point
apparatus, and are uncorrected. The melting points generally depend
on the purity level of the samples. Typically, bimatoprost
crystalline form I has been found to have a melting point between
62 and 64.degree. C.
[0102] Measurements of difference between the temperature of a
sample and a reference pan that are subject to the same temperature
program (differential scanning calorimetry, DSC) were obtained on a
Mettler-Toledo DSC 822e Differential Scanning calorimeter.
Example 1
(3aR,4R,5R,6aS)-4-(3-Oxo-5-phenyl-1E-pentenyl)-5-(4-phenylbenzoyloxy)-hexa-
hydro-2H-cyclopenta[b]furan-2-one
##STR00028##
[0104] A solution of (-)-Corey lactone 5-(4-phenylbenzoate) 9 (17.6
g, 50.0 mmol) and TEMPO (0.16 g, 1.0 mmol) in CH.sub.2Cl.sub.2 (100
mL) was added to a solution of NaBr (0.5 g, 5.0 mmol), NaHCO.sub.3
(12.6 g, 150.0 mmol) and IPA (6.0 g, 100.0 mmol) in water (100 mL).
5% aq. NaOCl (about 150 mL) was added dropwise to the stirred
mixture at -5 to 0.degree. C. until disappearance of Corey lactone
(TLC monitoring). The obtained mixture was stirred for 0.5 h at the
same temperature. The aqueous layer was separated and extracted
with CH.sub.2Cl.sub.2 (50 mL). The combined organic layers was
added dropwise over 1 h to a stirred mixture of a solution of
BnCH.sub.2COCH.sub.2PO(OMe).sub.2 (15.4 g, 60.0 mmol) in
CH.sub.2Cl.sub.2 (20 mL) and 30% NaOH (8.0 g, 60.0 mmol) at
0-5.degree. C. The mixture was stirred 0.5 h at the same
temperature and treated with 10% aq. citric acid (100 mL). The
aqueous layer was separated and extracted with CH.sub.2Cl.sub.2 (50
mL). The combined organic layers were dried over Na.sub.2SO.sub.4,
filtered through short silica gel column and concentrated in vacuo.
The oily residue (24.2 g) was dissolved in refluxed EtOH (150 mL)
and cooled in ice bath. The precipitate was filtered off, washed
with cold EtOH and dried in vacuo to give 20.1 g (84%) of ketone 7
with 99.4% purity by HPLC: mp 129-130.degree. C.,
[.alpha.].sup.20.sub.D -142.degree. (c 1.0, CHCl.sub.3); .sup.1H
NMR (CDCl.sub.3) .delta. 2.32-2.63 (m, 3H); 2.84-2.97 (m, 7H);
5.00-5.10 (m, 1H); 5.20-5.35 (m, 1H); 6.20 (d, J=16 Hz, 1H); 6.65
(dd, J=16 and 8 Hz, 1H); 7.15-7.67 (m, 12H); 8.03 (d, J=8 Hz,
2H).
Example 2
(3aR,4R,5R,6aS)-4-[3R- and
3S-hydroxy-5-phenyl-1E-pentenyl]-5-(4-phenylbenzoyloxy)-hexahydro-2H-cycl-
openta[b]furan-2-ones (mixture of 3R- and 3S-isomers)
##STR00029##
[0106] A solution of (-)-DIP-Chloride.TM. (77.0 g, 0.24 mol) in
CH.sub.2Cl.sub.2 (150 mL) was added dropwise during 2 h to a
stirred solution of ketone 7 (57.7 g, 0.12 mol) in CH.sub.2Cl.sub.2
(300 mL) at -25 to -30.degree. C. The mixture was stirred overnight
at the same temperature and treated with MeOH (100 mL) at rt. The
obtained mixture was stirred for 0.5 h and washed with 20% aq.
NH.sub.4Cl (250 mL). The aqueous layer was separated and extracted
with CH.sub.2Cl.sub.2 (2.times.100 mL). The combined organic layers
were dried over Na.sub.2SO.sub.4, filtered and concentrated in
vacuo. The residue was crystallized from MeOH to give 49.8 g (86%)
of mixture alcohols 6 and 6a with 6/6a ratio about 97:3 by
HPLC.
Example 3
(3aR,4R,5R,6aS)-4-[3S-(t-Butyldimethylsiloxy)-5-phenyl-1E-pentenyl]-5-(4-p-
henylbenzoyloxy)-hexahydro-2H-cyclopenta[b]furan-2-one 5
##STR00030##
[0108] A mixture of alcohols 6 and 6a with 6/6a ratio about 97:3 by
HPLC (15.4 g, 32.0 mmol), CH.sub.2Cl.sub.2 (75 mL),
t-BuMe.sub.2SiCl (7.2 g, 48.0 mmol) and imidazole (6.5 g, 96.0
mmol) was refluxed for 1 h and mixed with 10% aq. citric acid (50
mL). The aqueous layer was separated and extracted with
CH.sub.2Cl.sub.2 (50 mL). The combined organic layers were dried
over Na.sub.2SO.sub.4, filtered through the column with silica gel
(30 g) and concentrated in vacuo. The residue was crystallized from
MTBE to give 16.2 g (76%) of
(3aR,4R,5R,6aS)-4-[3S-(t-butyldimethylsiloxy)-5-phenyl-1E-pentenyl]-5-(4--
phenylbenzoyloxy)-hexahydro-2H-cyclopenta[b]furan-2-one 5 as MTBE
solvate with 99.8% purity by HPLC: mp 60-64.degree. C.;
[.alpha.].sup.20.sub.D -84.degree. (c 1, MeCN); .sup.1H NMR
(CDCl.sub.3) .delta. 8.04 (d, J=8 Hz, 2H), 7.60 (m, 4H), 7.42 (m,
3H), 7.15 (m, 5H), 5.58 (m, 2H), 5.22 (q, J=5.5 Hz, 1H), 5.01 (t,
J=5.5 Hz, 1H), 4.12 (q, J=5.5 Hz, 1H), 3.18 (s, 3H), 2.69 (m, 7H),
2.20 (m, 1H), 1.79 (m, 2H), 1.17 (s, 9H), 0.85 (s, 9H), -0.02 (d,
J=12 Hz, 6H).
[0109] The x-ray powder diffraction pattern of crystalline MTBE
solvate of compound 5 has characteristic peaks expressed in degrees
20 at approximately 6.5, 7.1, 12.2, 12.5, 13.1, 13.6, 14.6, 15.0,
15.8, 16.2, 16.3, 17.0, 17.3, 18.0, 18.2, 18.8, 19.5, 19.7, 20.5,
20.8, 21.0, 21.8, 22.2, 23.0, 23.3, 24.2, 25.5, 26.5 and 26.7.
[0110] IR DRIFTS (KBr): 2949, 2931, 2854, 1765, 1715, 1607, 1361,
1266, 1203, 1170, 1118, 1095, 1080, 972, 912, 852, 839, 775, 745,
and 699 cm.sup.-1.
[0111] Compound 5 MTBE solvate was characterized by .sup.1H NMR
(CDCl.sub.3), powder x-ray diffractometry, IR DRIFTS (KBr)
spectroscopy, DSC and TGA as set forth above and in FIGS. 6, 7, 8,
9 and 10.
Example 4
Preparation of
(3aR,4R,5R,6aS)-4-[3S-(t-butyldimethylsiloxy)-5-phenyl-1E-pentenyl]-5-(4--
phenylbenzoyloxy)-hexahydro-2H-cyclopenta[b]furan-2-one 5 and
(3aR,4R,5R,6aS)-4-[3R-(t-butyldimethylsiloxy)-5-phenyl-1E-pentenyl]-5-(4--
phenylbenzoyloxy)-hexahydro-2H-cyclopenta[b]furan-2-one 5a
##STR00031##
[0113] NaBH.sub.4 (1.7 g, 44 mmol) was added in three portions to a
stirred mixture of ketone 7 (21.0 g, 43.7 mmol), CH.sub.2Cl.sub.2
(125 mL) and MeOH (125 mL) at 0-4.degree. C. during 1 h. The
obtained mixture was stirred for 1 h at 0-4.degree. C. and
concentrated in vacuo. A mixture of the residue, CH.sub.2Cl.sub.2
(200 mL) and 5% NaHCO.sub.3 (100 mL) was stirred for 1 h at
25.degree. C. The aqueous phase was separated and extracted with
CH.sub.2Cl.sub.2 (50 mL). The combined organics were washed with 5%
NaHCO.sub.3 (30 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo to give 20.0 g (95%) of mixture 6 and 6a with
ratio 6/6a .about.1:1.
[0114] A solution of the residue (20.0 g, 41.4 mmol) and imidazole
(4.3 g, 62.2 mmol) in CH.sub.2Cl.sub.2 (200 mL) was treated with a
solution of t-BuMe.sub.2SiCl (7.5 g, 49.7 mmol) in CH.sub.2Cl.sub.2
(30 mL). The resulted suspension was refluxed for 2 h, cooled to
10.degree. C. and quenched by addition of 10% aq citric acid (60
mL). The phases were separated, the organic one was washed with
water (100 mL) and 10% NaHCO.sub.3 (30 mL), dried over
Na.sub.2SO.sub.4, filtered and passed through silica gel (30 g).
The column was washed with CH.sub.2Cl.sub.2 (300 mL) and the
combined filtrates were evaporated under reduced pressure to give
25.0 g of mixture 5 and 5a with ratio 5/5a .about.1:1. The residue
(25 g) was crystallized from MTBE (100 mL) to give 9.3 g of crude
lactone 5 MTBE solvate (0.6% of 5a) as white solid. The crude
product was re-crystallized from MTBE (80 mL) affording 8.5 g (30%
from ketone 7) of lactone 5 MTBE solvate (0.02% of 5a) as white
crystalline powder. mp 60-64.degree. C.; [.alpha.].sup.20.sub.D
-84.degree. (c 1, MeCN).
[0115] All filtrates were combined and concentrated in vacuo. A
mixture of the residue (18.0 g), heptane (165 mL) and toluene (15
mL) was stirred for 0.5 h at 70.degree. C. and for 12 h at rt. The
precipitate was filtered off, washed with heptane on the filter and
dried in vacuo to give 8.0 g of crude lactone 5a preferably (4% of
5). Two additional crystallizations of the crude product afforded
6.0 g (24% from ketone 7) of lactone 5a as white crystalline powder
with 99.7% purity (0.2% of 5) by HPLC, mp 93-94.degree. C. and
[.alpha.].sub.D.sup.20 -92.degree. (c 1, CHCl.sub.3).
[0116] All filtrates were combined again, evaporated and treated as
described above to give additionally 2.8 g (10% from ketone 7) of
lactone 5 MTBE solvate and 2.2 g (9% from ketone 7) of lactone 5a.
Total 11.3 g (40% from ketone 7) of lactone 5 MTBE solvate and 8.2
g (33% from ketone 7) of lactone 5a was prepared.
[0117]
(3aR,4R,5R,6aS)-4-[3S-(t-Butyldimethylsiloxy)-5-phenyl-1E-pentenyl]-
-5-(4-phenylbenzoyloxy)-hexahydro-2H-cyclopenta[b]furan-2-one MTBE
solvate was characterized by .sup.1H NMR (CDCl.sub.3), powder x-ray
diffractometry, IR DRIFTS (KBr) spectroscopy, DSC and TGA as set
forth above and in FIGS. 6-10.
[0118] (3a
R,4R,5R,6aS)-4-[3R-(t-butyldimethylsiloxy)-5-phenyl-1E-pentenyl-
]-5-(4-phenylbenzoyloxy)-hexahydro-2H-cyclopenta[b]furan-2-one 5a:
H.sup.1 NMR (200 MHz) .delta. 8.00 (d, 2H, J 8.3 Hz), 7.58 (m, 4H),
7.35 (m, 3H), 7.15 (m, 3H), 7.06 (t, 2H, J 7.1 Hz), 5.60 (m, 2H),
5.22 (dd, 1H, J.sub.1 6.1 Hz, J.sub.2 12.0 Hz), 5.04 (dd, J.sub.1
4.3 Hz, J.sub.2 12.0 Hz), 4.11 (q, 1H, J 5.8 Hz), 2.85-2.44 (m,
7H), 2.20 (m, 1H), 1.73 (m, 2H), 0.85 (m, 9H), -0.02 (d, 6H, J 7.3
Hz).
[0119] The x-ray powder diffraction pattern of crystalline
(3aR,4R,5R,6aS)-4-[3R-(t-butyldimethylsiloxy)-5-phenyl-1E-pentenyl]-5-(4--
phenylbenzoyloxy)-hexahydro-2H-cyclopenta[b]furan-2-one 5a has
characteristic peaks expressed in degrees 20 at approximately 5.7,
6.3, 14.0, 14.5, 14.8, 15.5, 16.3, 17.0, 17.5, 17.8, 18.1, 18.6,
18.9, 19.3, 21.5, 22.0, 22.4 and 23.8. IR (KBr): 3428.8, 3061.1
3027.7, 2952.1, 2928.7, 2884.0, 2855.8, 1761.7, 1714.4, 1608.2,
1487.6, 1471.1, 1454.3, 1404.6, 1360.1, 1313.0, 1276.0, 1181.3,
1114.1, 1082.5, 1061.0, 1006.6, 974.3, 901.8, 869.0, 836.1, 776.6,
748.2, 698.6, and 670.0 cm.sup.-1.
[0120] Lactone 5a was characterized by .sup.1H NMR (CDCl.sub.3),
powder x-ray diffractometry, DSC, and IR (KBr) spectroscopy as set
forth above and illustrated in FIGS. 11-14.
Example 5
Preparation of
(3aR,4R,5R,6aS)-4-[3S-(t-butyldimethylsiloxy)-5-phenyl-1E-pentenyl]-5-(4--
phenylbenzoyloxy)-hexahydro-2H-cyclopenta[b]furan-2-one 5
##STR00032##
[0122] A solution of (-)-DIP-Chloride.TM. (282.3 g, 0.88 mol) in
CH.sub.2Cl.sub.2 (500 mL) was added dropwise during 2 h to a
stirred solution of ketone 7 (210.0 g, 0.44 mol) in
CH.sub.2Cl.sub.2 (1.6 L) at -25 to -30.degree. C. The mixture was
stirred 12 h at the same temperature, heated to -3.degree. C. and
treated with 10% aq. NH.sub.4Cl (400 mL). The obtained mixture was
stirred for 1 h at rt. The aqueous layer was separated and
extracted with CH.sub.2Cl.sub.2 (2.times.150 mL). The combined
organic layers were dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo to a half of volume. A mixture of the residue
and imidazole (179.8 g, 2.64 mol) was treated with a solution of
t-BuMe.sub.2SiCl (265.3 g, 1.76 mol) in CH.sub.2Cl.sub.2 (500 mL).
The resulted suspension was refluxed for 2 h, cooled to 10.degree.
C. and quenched by addition of 10% aq citric acid (1.5 L). The
phases were separated, the organic one was washed with water (300
mL) and 10% NaHCO.sub.3 (300 mL), dried over Na.sub.2SO.sub.4,
filtered and passed through silica gel (250 g). The column was
washed with CH.sub.2Cl.sub.2 (2 L) and the combined filtrates were
evaporated under reduced pressure. The residue (350 g) was
crystallized from MTBE (2.4 L) to give 232.0 g of crude lactone 5
MTBE solvate (0.6% of 5a) as white solid. The crude product was
re-crystallized from MTBE (2 L) affording 217 g (72% from ketone 7)
of lactone 5 MTBE solvate (0.02% of 5a) as white crystalline
powder.
Example 6
(3aR,4R,5R,6aS)-4-(3S-hydroxy-5-phenyl-1E-pentenyl)-5-hydroxy-hexahydro-2H-
-cyclopenta[b]furan-2-one 6
##STR00033##
[0124] Method A. A mixture of compound 5 MTBE solvate (0.69 g, 1.2
mmol), 1 M solution of Bu.sub.4NF in THF (1.4 mL, 1.4 mmol) and THF
(4 mL) was stirred for 3 h at rt and treated with water (20 mL).
The obtained mixture was extracted with MTBE. The combined organic
extracts were dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The residue was crystallized from MeOH to
give alcohol 6 as white crystals with mp 126-128.degree. C.:
.sup.1H NMR (CDCl.sub.3) is in agreement with the structure.
[0125] Method B. A mixture of compound 5 MTBE solvate (1.0 g, 1.7
mmol), 32% HCl (0.1 mL, 0.3 mmol) and MeOH (6 mL) was stirred for 2
h at 40.degree. C. and for 2 h at 0 to 5.degree. C. The precipitate
was filtered off, washed on the filter with cold MeOH and dried in
vacuo to give alcohol 6 as white crystals.
Example 7
(3aR,4R,5R,6aS)-4-(3R-hydroxy-5-phenyl-1E-pentenyl)-5-hydroxy-hexahydro-2H-
-cyclopenta[b]furan-2-one 6a
##STR00034##
[0127] Cleavage of silyl-protective group of compound 5a following
by column chromatography purification on silica gel gives alcohol
6a as white crystals with mp 81-83.degree. C. (Et.sub.2O/hexane):
[.alpha.].sub.D.sup.20 -124.5.degree. (c 1, MeCN); .sup.1H NMR
(CDCl.sub.3) .delta.: 7.08-8.05 (m, 14H); 5.51-5.74 (m, 2H);
5.21-5.30 (m, 1H); 5.02-5.07 (m, 1H); 4.09-4.13 (m, 1H); 2.46-2.92
(m, 7H); 2.18-2.28 (m, 1H); 1.66-1.86 (m, 3H). .sup.13C(CDCl.sub.3)
.delta.: 31.6; 34.8; 37.6; 38.7; 42.7; 54.1; 71.6; 79.0; 83.1;
125.9; 127.1; 127.2; 128.2; 128.3; 128.8; 128.9; 130.1; 136.2;
139.9; 141.5; 146.1; 165.9; 176.2.
Example 8
(3aR,4R,5R,6aS)-4-(3-oxo-5-phenyl-1E-pentenyl)-5-hydroxy-hexahydro-2H-cycl-
openta[b]furan-2-one 7
##STR00035##
[0129] Method A. A solution of C.sub.5H.sub.5N.SO.sub.3 (0.32 g) in
DMSO (3.5 mL) was added dropwise to a stirred solution of alcohol
6a (0.30 g) and Et.sub.3N (0.40 g) in CH.sub.2Cl.sub.2 (4 mL) at -5
to 0.degree. C. The mixture was stirred at the same temperature for
1 h (TLC monitoring) and poured into cold water (15 mL). The
mixture was stirred for 10 min at 0-5.degree. C. The organic layer
was separated, the water layer was extracted with CH.sub.2Cl.sub.2
(3.times.5 mL). The combined organic layers were washed with brine
(3.times.10 mL), dried over Na.sub.2SO.sub.4, filtered and
evaporated under reduced pressure. A solution of the residue in
MeOH (1 mL) was cold to -10.degree. C. and kept at the same
temperature for 3 h. The precipitated crystals were filtered,
washed on filter with cold MeOH (2.times.1 mL) and dried under
reduced pressure to a constant weight to give 0.26 g (87% yield) of
crude ketone 7 with 94% purity by HPLC. The crude ketone 7 was
recrystallizated from MeOH gave crystalline ketone 7 with mp
134-135.degree. C. and [.alpha.].sub.D.sup.20 -141.7.degree. (c
1.26, MeCN).
[0130] Method B. 5% aq. NaOCl (40 mL, TLC monitoring) was added
dropwise to a stirred mixture of alcohol 6a (0.53 g, 1.1 mmol),
TEMPO (4 mg, 0.025 mmol), NaBr (12 mg, 0.12 mmol), NaHCO.sub.3 (0.3
g, 3.6 mmol), CH.sub.2Cl.sub.2 (3 mL) and water (3 mL) at rt and
the mixture was stirred for 1 h. The aqueous layer was separated
and extracted with CH.sub.2Cl.sub.2 (3 mL). The combined organic
layer was dried over Na.sub.2SO.sub.4 and filtered trough short
silica gel column. The residue was concentrated in vacuo and
crystallized from MeOH (5 mL) to give 0.37 g (70%) of ketone 7.
Example 9
(3aR,4R,5R,6aS)-4-[3S-(t-butyldimethylsiloxy)-5-phenyl-1E-pentenyl]-5-hydr-
oxy-hexahydro-2H-cyclopenta[b]furan-2-ol 4
##STR00036##
[0132] i-Bu.sub.2AlH (20% w/w solution in toluene, 59.5 mL, 72
mmol) was added dropwise to a stirred solution of lactone 5 MTBE
solvate (15.0 g, 21.8 mmol) in toluene (100 mL) at -25 to
-20.degree. C. The mixture was stirred for 1 h at the same
temperature, heated to -10.degree. C. and quenched by slow addition
of 10% aq citric acid (210 g, 109 mmol) keeping reaction
temperature below 20.degree. C. The resulted suspension was stirred
for 1 h at rt until most of solids disappeared. The aqueous phase
was separated and extracted with toluene (50 mL). The combined
organics were washed with 5% NaHCO.sub.3 (50 mL), dried over
Na.sub.2SO.sub.4, filtered and passed through silica gel column (80
g). The column was eluted with CH.sub.2Cl.sub.2 (1 L) and then with
the mixture CH.sub.2Cl.sub.2/EtOAc 1:1 (1 L), the fractions
containing lactol 4 were combined and concentrated in vacuo to give
9.0 g (99%) of lactol 4 with 98.5% purity by HPLC.
Example 10
(3aR,4R,5R,6aS)-4-[3R-(t-butyldimethylsiloxy)-5-phenyl-1E-pentenyl]-5-hydr-
oxy-hexahydro-2H-cyclopenta[b]furan-2-ol 4a
##STR00037##
[0134] i-Bu.sub.2AlH (20% w/w in toluene, 50 mL, 60.0 mmol) was
added dropwise to a stirred solution of lactone 5a (10.74 g, 18.0
mmol) in toluene (70 mL), at -25 to -15.degree. C. The mixture was
stirred at the same temperature for 2 h, then heated to -10.degree.
C. and quenched by slow addition of 10% aq citric acid (173 mL,
90.0 mmol). The resulted mixture was stirred for 1 h at rt until
the most of solids were disappeared. The aqueous phase was
separated and extracted with toluene (50 mL). The combined organics
were washed with 5% NaHCO.sub.3 (50 mL), dried over
Na.sub.2SO.sub.4, filtered and passed through silica gel column (60
g). The column was eluted with CH.sub.2Cl.sub.2 (1 L) and then with
the mixture CH.sub.2Cl.sub.2/EtOAc 1:1 (1 L), the fractions
containing the lactol 4a were combined and concentrated in vacuo to
give 7.5 g (%) of lactol 4a as viscous oil with 98.5% purity by
HPLC.
Example 11
Bimatoprost Acid 3
##STR00038##
[0136] t-BuOK (19.4 g, 172.0 mmol) was added in three portions to a
mixture of HOOC(CH.sub.2).sub.4PPh.sub.3.sup.+ Br.sup.- (38.3 g,
86.0 mmol) and THF (mL) at -5 to 0.degree. C. The obtained mixture
was stirred for 0.5 h at the same temperature and a solution of
lactol 4 (9.0 g, 21.5 mmol) in dry THF (50 mL) was slowly added.
The mixture was stirred for 10 h at 0 to 5.degree. C. and quenched
by addition of water (200 mL). The pH of the mixture was adjusted
to 7.5-8.0 with 20% aq citric acid, most of THF was evaporated in
vacuo and extracted with MTBE (3.times.150 mL). The combined
organics were washed with 5% NaHCO.sub.3 (adjusted to pH 8 with 20%
aq citric acid, 2.times.100 mL) and brine, and concentrated in
vacuo. The residue was dissolved in MeOH (80 mL), the solution was
cooled to 0.degree. C., and 3 N HCl (21.5 mL, 64.5 mmol) was slowly
added keeping reaction temperature below 10.degree. C. The resulted
mixture was stirred for 5 h at 0 to 5.degree. C. and quenched by
addition of 10% NaOH (44 g, 110 mmol). The mixture was stirred for
1 h at 40.degree. C., most of MeOH was evaporated in vacuo and the
aqueous phase was extracted with MTBE (4.times.70 mL). The combined
organics were washed with 10% NaOH (40 mL), the aqueous layers were
combined and acidified to pH 3.5-4.5 with 20% aq citric acid. The
resulted mixture was extracted with MTBE (3.times.100 mL), the
combined organics were washed with brine, dried over
Na.sub.2SO.sub.4, filtered and passed through silica gel column (45
g). The column was eluted with MTBE (500 mL) and EtOAc (800 mL),
the fractions containing bimatoprost acid were combined and
concentrated in vacuo to give 7.5 g (90%) of bimatoprost acid 3 as
slight yellow semisolid mass. Analytical HPLC showed that the
product contained about 3.5% of the 5-trans isomer (from the Wittig
reaction).
Example 12
15R-Bimatoprost Acid 3a
##STR00039##
[0138] t-BuOK (16.2 g, 144.0 mmol) was added in three portions to a
stirred mixture of HOOC(CH.sub.2).sub.4PPh.sub.3.sup.+ Br.sup.-
(31.9 g, 72.0 mmol) and THF (mL) at -5.degree. C. The mixture was
stirred for 0.5 h at -3.degree. C. and a solution of lactol 4a (7.5
g, 18.0 mmol) in dry THF (50 mL) was slowly added. The mixture was
stirred for 10 h at 0.degree. C. and quenched by addition of water
(200 mL). The pH of the mixture was adjusted to 7.5-8.0 with 20% aq
citric acid, the most of THF was evaporated and the aqueous mixture
was extracted with MTBE (3.times.120 mL). The combined organics
were washed with 5% NaHCO.sub.3 (adjusted to pH 7.7-8.0 with 20% aq
citric acid, 2.times.30 mL) and brine and concentrated in vacuo. A
solution of the residue in MeOH (50 mL) was treated with 3 N HCl
(15 mL) at 0.degree. C. The resulted mixture was stirred for 4 h at
0-4.degree. C. and quenched by addition of 10% NaOH (44 mL). The
mixture was stirred for 1 h at 40.degree. C., the most of MeOH was
evaporated in vacuo and the aqueous phase was extracted with MTBE
(4.times.70 mL). The combined organics were washed with 10% NaOH
(30 mL), the aqueous layers were combined and acidified to pH
3.5-4.5 with 20% aq citric acid. The resulted mixture was extracted
with MTBE (3.times.100 mL), the combined organics were washed with
brine, dried over Na.sub.2SO.sub.4, filtered and passed through
silica gel column (60 g). The column was eluted with
CH.sub.2Cl.sub.2 (300 mL), CH.sub.2Cl.sub.2/EtOAc 1:1 (300 mL) and
EtOAc (600 mL), the fractions containing 3a were combined and
concentrated in vacuo to give 4.6 g (65%) of 15R-bimatoprost acid
3a as yellow oil.
Example 13
Methyl Ester of Bimatoprost Acid 2
##STR00040##
[0140] A mixture of bimatoprost acid 3 (7.5 g, 19.3 mmol), MeI (1.8
mL, 29.0 mmol), Cs.sub.2CO.sub.3 (7.6 g, 23.2 mmol) and DMF (50 mL)
was stirred for 4 h at 0 to 4.degree. C., acidified to pH 4 with 3%
aq citric acid, heated to rt and extracted with MTBE (3.times.70
mL). The combined organics were washed with 5% NaHCO.sub.3 (50 mL),
dried over Na.sub.2SO.sub.4, filtered and concentrated in vacuo to
give 7.6 g (98%) of ester 2 as oil.
Example 14
Methyl Ester of 15R-Bimatoprost Acid 2a
##STR00041##
[0142] A mixture of acid 3a (4.3 g, 11.0 mmol), MeI (2.3 g, 16.0
mmol), Cs.sub.2CO.sub.3 (5.2 g, 16.0 mmol) and DMF (30 mL) was
stirred for 4 h at 0-4.degree. C., acidified to pH 4 with 3% aq
citric acid (120 mL), heated to rt and extracted with MTBE
(3.times.40 mL). The combined organics were washed with 5%
NaHCO.sub.3 (50 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo The residue was purified by chromatography on
silica gel (30 g, eluted with CH.sub.2Cl.sub.2,
CH.sub.2Cl.sub.2/EtOAc 1:1, 300 mL and then EtOAc 600 mL) to give
4.0 g (91%) of ester 2a as oil.
Example 15
15R-Bimatoprost 1a
##STR00042##
[0144] A mixture of ester 2a (3.0 g, 7.5 mmol), 70% aq EtNH.sub.2
(15 mL, 189 mmol) and MeOH (15 mL) was stirred for 72 h at rt in
well-closed flask and concentrated in vacuo. The oil residue was
portioned between EtOAc (100 mL) and water (60 mL). The aqueous
phase was separated and extracted with EtOAc (30 mL). The combined
organics were washed with 10% NaHCO.sub.3 (2.times.30 mL) and
brine, dried over Na.sub.2SO.sub.4, filtered and concentrated in
vacuo. The residue was purified by chromatography on a silica gel
column (30 g, eluted with EtOAc then EtOAc/MeOH 10:1) to give 2.4 g
(79%) of 15R-bimatoprost 1a as light yellow viscous oil.
Example 16
Methyl ester of tri(tert-butyldimethylsilyl) bimatoprost acid
10
##STR00043##
[0146] A mixture of ester 2a (3.30 g, 8.2 mmol), imidazole (5.58 g,
82.0 mmol) and t-BuMe.sub.2SiCl (6.18 g, 41.0 mmol) in DMF (20 mL)
was stirred overnight at rt and the reaction was quenched by
addition of 10% aq citric acid (100 mL). The mixture was extracted
with MTBE (3.times.30 mL), the combined organics were washed with a
10% NaHCO.sub.3 (30 mL), dried over Na.sub.2SO.sub.4, filtered and
concentrated in vacuo. The residue was purified on a silica gel (70
g, eluted with heptane, then heptane/EtOAc 10:1) to give 6.01 g
(98%) of ester 10 as light oil.
Example 17
Methyl ester of tri(tert-butyldimethylsilyl)-5-trans bimatoprost
acid 11
##STR00044##
[0148] A mixture of ester 10 (6.00 g, 8.0 mmol) and Ph.sub.2S.sub.2
(0.35 g, 0.16 mmol) in toluene (60 mL) was irradiated with 400W
halogen lamp under reflux conditions for 8 h and concentrated in
vacuo. The residue was purified on a silica gel (70 g, eluted with
heptane, then heptane/EtOAc 10:1) to give 5.51 g of mixture trans-
and cis-isomers with ratio about 4 to 1. This mixture was separated
on a silica gel modified with AgNO.sub.3 (24.0 g of AgNO.sub.3 on
200.0 g of silica gel, eluted with heptane then heptane/toluene
50:1) to give 3.85 g (70%) of ester 11 as transparent viscous
oil.
Example 18
Methyl ester of 5-trans bimatoprost acid 2b
##STR00045##
[0150] A mixture of ester 2b (3.73 g, 5.0 mmol) and Bu.sub.4NF (1 M
solution in THF, 25 mL, 25.0 mmol) was stirred 14 h at rt and
concentrated in vacuo. A solution of the residue in
CH.sub.2Cl.sub.2 was washed with 10% aq citric acid, dried over
Na.sub.2SO.sub.4, filtered and concentrated in vacuo. The residue
was purified by chromatography on a silica gel (30 g, eluent
CH.sub.2Cl.sub.2, then CH.sub.2Cl.sub.2/EtOAc 1:1) to give 1.65 g
(82%) of ester 2b.
Example 19
5-trans Bimatoprost 1b
##STR00046##
[0152] A solution of ester 2b (1.21 g, 3.0 mmol) in the mixture of
MeOH (8 mL) and 70% aq EtNH.sub.2 (8 mL, 101 mmol) was stirred in
the well-closed flask for 72 h at rt. The volatiles were removed
under reduced pressure and the oil residue was dissolved in
CH.sub.2Cl.sub.2 and purified on a silica gel (30 g, eluent EtOAc
then EtOAc/MeOH 10:1) to give 1.03 g (83%) of 5-trans bimatoprost
1b as light yellow viscous oil.
Example 20
15-keto Bimatoprost 1c
##STR00047##
[0154] A mixture of bimatoprost 1 (0.33 g, 0.8 mmol), DDQ (0.68 g,
3.0 mmol), CH.sub.2Cl.sub.2 (5 mL) and 1,4-dioxane (5 mL) was
stirred for 24 h at 40.degree. C. and evaporated in vacuo. The
residue was purified by chromatography on a silica gel (20 g,
eluent EtOAc then EtOAc/MeOH 20:1) to give 0.21 g (63%) of 15-keto
bimatoprost 1c as yellow oil.
Example 21
Bimatoprost Form I
##STR00048##
[0156] A mixture of ester 2 [9.0 g, 22.4 mmol, contain (by HPLC)
3.5% of 5-trans isomer], 70% aq EtNH.sub.2 (40 mL, 503 mmol) and
MeOH (45 mL) was stirred in a well closed flask at 24 to 27.degree.
C. for 72 h and concentrated in vacuo. The residue was portioned
between EtOAc (100 mL) and water (60 mL). The phases were
separated, the aqueous one was extracted with EtOAc (30 mL) and the
combined organics were washed with 10% NaHCO.sub.3 (2.times.30 mL)
and brine, dried over Na.sub.2SO.sub.4, filtered and concentrated
in vacuo to give 8.0 g (86%) of crude bimatoprost containing 3.5%
(by HPLC) of 5-trans isomer 1b. The crude bimatoprost was
crystallized from a mixture of EtOAc (27 mL) and MTBE (54 mL) as
follows: dissolving the crude bimatoprost at or near the boiling
point and allowing the hot solution to cool to rt. Additional MTBE
(40 mL) was added and the mixture was stirred for 2 h at 0 to
5.degree. C. The precipitate was filtered off, washed on the filter
with cold MTBE (2.times.20 mL) and dried in vacuo for 1 h at 0 to
5.degree. C., for 0.5 h at rt and for 2 h at 30 to 40.degree. C. to
give 7.5 g (80%) of bimatoprost crystalline form I as white solid
with 98% purity by HPLC, less than 1% of 5-trans isomer 1b. The
bimatoprost (7.5 g) was crystallized from EtOAc (75 mL) as follows:
dissolving the bimatoprost at or near the boiling point, allowing
the hot solution to cool to rt, keeping the mixture for 1 h at rt
and for 2 h at 0 to 5.degree. C. The precipitate was filtered off
and dried in vacuo for 1 h at 0 to 5.degree. C., for 0.5 h at rt
and for 2 h at 30 to 40.degree. C. to give 6.7 g (90% recovery) of
bimatoprost crystalline form I as white powder with 99% purity by
HPLC, 0.6% 5-trans isomer 1b, NMT 0.1% of 15R-isomer 1a, and NMT
0.1% of 15-keto bimatoprost 1c; mp 64-66.degree. C.;
[.alpha.].sub.D.sup.20+36.degree. (c 1, MeOH).
[0157] The x-ray powder diffraction pattern of bimatoprost
crystalline form I has characteristic peaks expressed in degrees 20
at approximately 5.4, 6.2, 10.9, 11.3, 13.7, 16.6, 17.5, 18.3,
18.6, 18.9, 19.4, 19.7, 19.9, 20.7, 20.9, 21.6, 22.7 and 28.2.
[0158] IR DRIFTS (KBr): 3426.6, 3390.7, 3320.8, 3083.3, 3059.3,
3010.8, 2911.8, 2863.8, 1618.1, 1544.8, 1495.6, 1453.5, 1370.0,
1344.6, 1316.0, 1289.1, 1259.9, 1247.9, 1150.6, 1096.4, 1053.4,
1026.3, 975.0, 919.7, 767.4, 746.0, 728.1, 697.7, 607.2 and 597.6
cm.sup.-1.
[0159] IR (KBr): 3414.9, 3326.6, 3085.5, 3025.1, 3011.5, 2929.6,
2914.2, 2864.9, 1644.8, 1619.2, 1546.2, 1496.2, 1454.6, 1372.9,
1346.0, 1317.3, 1290.4, 1260.9, 1249.3, 1229.4, 1203.6, 1151.9,
1097.2, 1054.5, 1028.6, 975.4, 920.5, 767.6, 747.5, 721.7, 698.9,
596.2, 545.9, 491.2 and 463.0 cm.sup.-1.
[0160] IR (Nujol): 3418.5, 3328.2, 3085.2, 3062.4, 2953.1, 2925.4,
2854.7, 1619.6, 1545.3, 1496.3, 1456.5, 1376.5, 1346.2, 1316.5,
1290.0, 1261.0, 1248.7, 1229.1, 1203.3, 1151.1, 1122.6, 1097.5,
1054.6, 1027.1, 975.9, 961.0, 920.3, 768.1, 721.8, 697.8, 595.7 and
545.4 cm.sup.-1.
[0161] Crystalline form I of bimatoprost was characterized by
powder x-ray diffractometry, DSC, IR DRIFTS (KBr), IR (KBr) and IR
(Nujol) spectroscopy as set forth above and illustrated in FIGS.
1-5.
Example 22
Purification of Crude Bimatoprost
[0162] Crude bimatoprost containing (by HPLC) 2% to 5% 5-trans
isomer was dissolved in mixture of EtOAc and MTBE at or near the
boiling point. The solution was slowly cooled to 0-5.degree. C. The
precipitate was filtered and dried in vacuo for 1 h at 0 to
5.degree. C., for 0.5 h at rt and for 2 h at 30 to 40.degree. C. to
give crystalline bimatoprost form I, containing (by HPLC) not more
than 1% of 5-trans isomer. Repeated crystallization procedures give
crystalline bimatoprost form I as white powder with not less than
99% purity (by HPLC), containing not more than 0.5% of 5-trans
isomer, not more than 0.1% of 15R-isomer 1a, and not more than 0.1%
of 15-keto bimatoprost 1c.
Example 23
Crystalline Form I of Bimatoprost
[0163] Bimatoprost with 98% purity (by HPLC), contain 1% of 5-trans
isomer (0.5 g) was crystallized from isopropylacetone (10 mL) as
follows: dissolving the bimatoprost at or near the boiling point,
allowing the hot solution to cool to rt, keeping the mixture for 1
h at rt and for 2 h at 0 to 5.degree. C. The precipitate was
filtered off and dried in vacuo for 1 h at 0 to 5.degree. C., for
0.5 h at rt and for 2 h at 30 to 40.degree. C. to give 0.4 g (80%
recovery) of bimatoprost crystalline form I as white powder with
99% purity (by HPLC), containing 0.6% of 5-trans isomer.
Example 24
Crystalline Form I of Bimatoprost
[0164] Bimatoprost with 98% purity (by HPLC), contain 1% of 5-trans
isomer (0.5 g) was crystallized from t-BuOAc (9 mL) as follows:
dissolving the bimatoprost at or near the boiling point, allowing
the hot solution to cool to rt, keeping the mixture for 1 h at rt
and for 2 h at 0 to 5.degree. C. The precipitate was filtered off
and dried in vacuo for 1 h at 0 to 5.degree. C., for 0.5 h at rt
and for 2 h at 30 to 40.degree. C. to give 0.45 g (90% recovery) of
bimatoprost crystalline form I as white powder with 99.2% purity
(by HPLC), containing 0.6% of 5-trans isomer.
Example 25
Crystalline Form I of Bimatoprost
[0165] Bimatoprost with 98% purity (by HPLC), contain 1% of 5-trans
isomer (0.7 g) was crystallized from BuOAc (5 mL) as follows:
dissolving the bimatoprost at or near the boiling point, allowing
the hot solution to cool to rt, keeping the mixture for 1 h at rt
and for 2 h at 0 to 5.degree. C. The precipitate was filtered off
and dried in vacuo for 1 h at 0 to 5.degree. C., for 0.5 h at rt
and for 2 h at 30 to 40.degree. C. to give 0.6 g (86% recovery) of
bimatoprost crystalline form I as white powder with 99.4% purity
(by HPLC), containing 0.5% of 5-trans isomer.
Example 26
Crystalline Form I of Bimatoprost
[0166] Bimatoprost with 98.5% purity (by HPLC), contain 0.8% of
5-trans isomer (0.5 g) was crystallized from EtOAc (5 mL) as
follows: dissolving the bimatoprost at or near the boiling point,
allowing the hot solution to cool to rt, keeping the mixture for 1
h at rt and for 2 h at 0 to 5.degree. C. The precipitate was
filtered off and dried in vacuo for 1 h at 0 to 5.degree. C., for
0.5 h at rt and for 2 h at 30 to 40.degree. C. to give 0.45 g (90%
recovery) of bimatoprost crystalline form I as white powder with
99.3% purity (by HPLC), containing 0.5% of 5-trans isomer, 0.05% of
15R-isomer and 0.01% of 15-keto bimatoprost.
Example 27
Crystalline Form I of Bimatoprost
[0167] Bimatoprost form A (prepared according to US2005/209337, 0.3
g) was crystallized from mixture of EtOAc (1.5 mL) and MTBE (3 mL)
as follows: dissolving the bimatoprost at or near the boiling
point, allowing the hot solution to cool to rt, keeping the mixture
for 1 h at rt and for 2 h at 0 to 5.degree. C. The precipitate was
filtered off and dried in vacuo for 1 h at 0 to 5.degree. C., for
0.5 h at rt and for 2 h at 30 to 40.degree. C. to give 0.25 g (83%
recovery) of bimatoprost crystalline form I as white powder.
Example 28
Crystalline Form I of Bimatoprost
[0168] Bimatoprost (0.4 g) was crystallized from mixture of MeOH
(0.5 mL) and MTBE (10 mL) as follows: dissolving the bimatoprost at
or near the boiling point, allowing the hot solution to cool to rt,
keeping the mixture for 1 h at rt and for 2 h at 0 to 5.degree. C.
The precipitate was filtered off and dried in vacuo for 1 h at 0 to
5.degree. C., for 0.5 h at rt and for 2 h at 30 to 40.degree. C. to
give 0.3 g (75% recovery) of bimatoprost crystalline form I as
white powder.
Example 29
Crystalline Form I of Bimatoprost
[0169] Bimatoprost (0.5 g) was crystallized from mixture of t-BuOH
(3 mL) and heptane (5 mL) as follows: dissolving the bimatoprost at
or near the boiling point, allowing the hot solution to cool to rt,
keeping the mixture for 1 h at rt and for 2 h at 0 to 5.degree. C.
The precipitate was filtered off and dried in vacuo for 1 h at 0 to
5.degree. C., for 0.5 h at rt and for 2 h at 30 to 40.degree. C. to
give 0.35 g (70% recovery) of bimatoprost crystalline form I as
white powder.
Example 30
Crystalline Form I of Bimatoprost
[0170] A mixture of oily bimatoprost (prepared according to U.S.
Pat. No. 5,352,708, 1.0 g) and ether (20 mL) was stirred for 0.5 h
at or near the boiling point, slowly cooled to 0-5.degree. C. The
precipitate was filtered and dried in vacuo for 1 h at 0 to
5.degree. C., for 0.5 h at rt and for 2 h at 30 to 40.degree. C. to
give 0.94 g (94% recovery) of bimatoprost crystalline form I as
white powder.
Example 31
Crystalline Form I of Bimatoprost
[0171] A mixture of bimatoprost (0.4 g) and heptane (10 mL) was
stirred at 70.degree. C. for 2 h, slowly cooled to 0-5.degree. C.,
filtered and dried in vacuo for 1 h at 0 to 5.degree. C., for 0.5 h
at rt and for 2 h at 30 to 40.degree. C. affording 0.38 g (95%
recovery) of bimatoprost crystalline form I as white solid.
Example 32
Crystalline Form I of Bimatoprost
[0172] Bimatoprost (0.4 g) was crystallized from toluene (6 mL) as
follows: dissolving the bimatoprost at 70.degree. C., allowing the
hot solution to cool to rt, keeping the mixture for 1 h at rt and
for 2 h at 0 to 5.degree. C. The precipitate was filtered off and
dried in vacuo for 1 h at 0 to 5.degree. C., for 0.5 h at rt and
for 2 h at 30 to 40.degree. C. to give 0.38 g (95% recovery) of
bimatoprost crystalline form I as white powder.
Example 33
Crystalline Form I of Bimatoprost
[0173] Bimatoprost form A containing 2.5% (by HPLC) of 5-trans
isomer (0.3 g) was crystallized from EtOAc (1.5 mL) and MTBE (3 mL)
as follows: dissolving the bimatoprost at or near the boiling
point, allowing the hot solution to cool to rt, keeping the mixture
for 1 h at rt and for 2 h at 0 to 5.degree. C. The precipitate was
filtered off and dried in vacuo for 1 h at 0 to 5.degree. C., for
0.5 h at rt and for 2 h at 30 to 40.degree. C. to give 0.25 g (83%
recovery) of bimatoprost crystalline form I as white powder with
99.0% purity by HPLC, 0.8% trans-isomer.
Example 34
Crystalline Form I of Bimatoprost
[0174] Bimatoprost (0.53 g) was crystallized from CH.sub.2Cl.sub.2
(3.0 g) as follows: dissolving the bimatoprost at or near the
boiling point, allowing the hot solution to cool to rt, keeping the
mixture for 1 h at rt and for 2 h at 0 to 5.degree. C. The
precipitate was filtered off, washed on the filter with cold (0 to
5.degree. C.) CH.sub.2Cl.sub.2 (2.0 g) and dried in vacuo for 1 h
at 0 to 5.degree. C., for 0.5 h at rt and for 2 h at 30 to
40.degree. C. to give 0.31 g (59% recovery) of bimatoprost
crystalline form I.
Example 35
Crystalline Form I of Bimatoprost
[0175] Bimatoprost (0.53 g) was crystallized from isobutyl methyl
ketone (15.06 g) as follows: dissolving the bimatoprost at
60.degree. C., allowing the hot solution to cool to rt, keeping the
mixture for 1 h at rt and for 2 h at 0 to 5.degree. C. The
precipitate was filtered off, washed on the filter with cold (0 to
5.degree. C.) isobutyl methyl ketone (2.0 g) and dried in vacuo for
1 h at 0 to 5.degree. C., for 0.5 h at rt and for 2 h at 30 to
40.degree. C. to give 0.52 g (98% recovery) of bimatoprost
crystalline form I.
Example 36
Crystalline Form I of Bimatoprost
[0176] Bimatoprost (0.50 g) was crystallized from t-BuOMe (71.7 g)
as follows: dissolving the bimatoprost at or near the boiling
point, allowing the hot solution to cool to rt, keeping the mixture
for 1 h at rt and for 2 h at 0 to 5.degree. C. The precipitate was
filtered off, washed on the filter with cold (0 to 5.degree. C.)
t-BuOMe (2.0 g) and dried in vacuo for 1 h at 0 to 5.degree. C.,
for 0.5 h at rt and for 2 h at 30 to 40.degree. C. to give 0.52 g
(98% recovery) of bimatoprost crystalline form I.
Example 37
Crystalline Form I of Bimatoprost
[0177] Bimatoprost (0.46 g) was crystallized from toluene (70.92 g)
as follows: dissolving the bimatoprost at 70.degree. C., allowing
the hot solution to cool to rt, keeping the mixture for 1 h at rt
and for 2 h at 0 to 5.degree. C. The precipitate was filtered off,
washed on the filter with cold (0 to 5.degree. C.) toluene (2.0 g)
and dried in vacuo for 1 h at 0 to 5.degree. C., for 0.5 h at rt
and for 2 h at 30 to 40.degree. C. to give 0.30 g (65% recovery) of
bimatoprost crystalline form I.
Example 38
Crystalline Form I of Bimatoprost
[0178] Bimatoprost (0.52 g) was crystallized from MeCN (10.6 g) as
follows: dissolving the bimatoprost at or near the boiling point,
allowing the hot solution to cool to rt, keeping the mixture for 1
h at rt and for 2 h at 0 to 5.degree. C. The precipitate was
filtered off, washed on the filter with cold (0 to 5.degree. C.)
MeCN (2.0 g) and dried in vacuo for 1 h at 0 to 5.degree. C., for
0.5 h at rt and for 2 h at 30 to 40.degree. C. to give 0.43 g (83%
recovery) of bimatoprost crystalline form I.
Example 39
Crystalline Form I of Bimatoprost
[0179] Bimatoprost (0.51 g) was crystallized from EtOAc (8.1 g) as
follows: dissolving the bimatoprost at or near the boiling point,
allowing the hot solution to cool to rt, keeping the mixture for 1
h at rt and for 2 h at 0 to 5.degree. C. The precipitate was
filtered off, washed on the filter with cold (0 to 5.degree. C.)
EtOAc (2.0 g) and dried in vacuo for 1 h at 0 to 5.degree. C., for
0.5 h at rt and for 2 h at 30 to 40.degree. C. to give 0.42 g (82%
recovery) of bimatoprost crystalline form I.
[0180] Although certain presently preferred embodiments of the
invention have been described herein, it will be apparent to those
skilled in the art to which the invention pertains that variations
and modifications of the described embodiments may be made without
departing from the spirit and scope of the invention. Accordingly,
it is intended that the invention be limited only to the extent
required by the appended claims and the applicable rules of
law.
* * * * *